At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 15 enrolled
Drug / intervention
Namenda/Memantinedrug
Likely dose
Namenda/Memantine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's) or Selective Serotonin Reuptake Inhibitors (SSRI's).
State University of New York - Upstate Medical University·interventional·Posted Dec 14, 2006·Updated Dec 10, 2014
In Brief
A Phase 3 clinical trial evaluating Namenda/Memantine for General Anxiety Disorder, Social Anxiety Disorder. Completed, enrolled 15 participants across 1 site.
Detailed Summary
This study is being conducted to evaluate the safety and effectiveness of memantine Add-On treatment of patients who are currently taking an SNRI or SSRI and who remain anxious and symptomatic despite treatment. Secondary objectives of this study are: •-to evaluate if there is an improvement in disability levels following memantine dosing -to evaluate if there is an improvement in sleep quality following memantine dosing
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedDec 2006
Primary CompletionMay 2010
TodayJul 2026
First PostedDec 14, 2006
Enrollment StartDec 1, 2006
Primary CompletionMay 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 19.6 years ago
Interventions
Namenda/Memantinedrug
5mg tablets, 1-4 tabs by mouth per day